Seel, what is the norm when a drug cocktail is concocted such as our KEVETRIN and Pfizer kinase inhibitors currently getting ready for trial?  Do the separate owners just have to hash it out on their own as to how much of the total revenue each gets should the cocktail go to production or is there some sort of std. revenue sharing agreement in the industry?  Interested as both KEVETRIN and PRURISOL seem to have vast potential for such cocktails.  The PR IMO indicated that preclinical tests show the CTIX/Pfizer combo to work well together.